Next year, the Ford Thunderbird returns as a vertical take-off and landing vehicle in a surprise move designed to compete with GM’s future Cadillac VTOL.
Colonel Mark M. Zais, chief data scientist at United States Special Operations Command (USSOCOM) stresses the importance of AI-related education in the DOD. In his 2020 CJCS Strategic Essay Competition first place Strategy Article, he says, “Without that education, we face a world where senior leaders use AI-enabled technologies to make decisions related to national security without a full grasp of the tools that they—and our adversaries—possess.”
With the release of its first artificial intelligence (AI) strategy in 2019, the Department of Defense (DOD) formalized the increased use of AI technology throughout the military, challenging senior leaders to create “organizational AI strategies” and “make related resource allocation decisions.”1 Unfortunately, most senior leaders currently have limited familiarity with AI, having developed their skills in tactical counterinsurgency environments, which reward strength (physical and mental), perseverance, and diligence. Some defense scholars have advocated a smarter military, emphasizing intellectual human capital and arguing that cognitive ability will determine success in strategy development, statesmanship, and decisionmaking.2 AI might complement that ability but cannot be a substitute for it. Military leaders must leverage AI to help them adapt and be curious. As innovative technologies with AI applications increasingly become integral to DOD modernization and near-peer competition, senior leaders’ knowledge of AI is critical for shaping and applying our AI strategy and creating properly calibrated expectations.
War is about decisionmaking, and AI enables the technology that will transform how humans and machines make those decisions.3 Successful use of this general-purpose technology will require senior leaders who truly understand its capabilities and can demystify the hyperbole.4 Within current AI strategy development and application, many practitioners have a palpable sense of dread as we crest the waves of a second AI hype cycle, seemingly captained by novices of the AI seas.5 In-house technical experts find it difficult to manage expectations and influence priorities, clouded by buzzwords and stifled by ambitions for “quick wins.” The importance of AI-related education increases with AI aspirations and the illusion of progress. Without that education, we face a world where senior leaders use AI-enabled technologies to make decisions related to national security without a full grasp of the tools that they—and our adversaries—possess. This would be equivalent to a combat arms officer making strategic military landpower decisions without the foundations of military education in maneuver warfare and practical experience.
Continue reading “Artificial Intelligence: A Decisionmaking Technology” »
Dr Joan Mannick, Head of Research and Development at Life Biosciences, discusses the #geroscience approach in disease treatment and the exciting work being done at Life Biosciences.
#Ageing is the greatest risk factor for almost every chronic disease. Multiple studies have shown that ageing is a modifiable risk factor that can be targeted therapeutically.
The European Organization for Nuclear Research (CERN) involves 23 countries, 15000 researchers, billions of dollars a year, and the biggest machine in the world: the Large Hadron Collider. Even with so much organizational and mechanical firepower behind it, though, CERN and the LHC are outgrowing their current computing infrastructure, demanding big shifts in how the world’s biggest physics experiment collects, stores and analyzes its data. At the 2021 EuroHPC Summit Week, Maria Girone, CTO of the CERN openlab, discussed how those shifts will be made.
The answer, of course: HPC.
The Large Hadron Collider – a massive particle accelerator – is capable of collecting data 40 million times per second from each of its 150 million sensors, adding up to a total possible data load of around a petabyte per second. This data describes whether a detector was hit by a particle, and if so, what kind and when.
Pugs, Ferraris, mountains, brunches, beaches, and babies — Instagram is full of them. In fact, it’s become one of the largest image databases on the planet over the last decade and the company’s owner, Facebook, is using this treasure trove to teach machines what’s in a photo.
Facebook announced on Thursday that it had built an artificial intelligence program that can “see” what it is looking at. It did this by feeding it over 1 billion public images from Instagram.
The “computer vision” program, nicknamed SEER, outperformed existing AI models in an object recognition test, Facebook said.
Researchers at Brown University have created a brain-computer interface (BCI) with 200 electrodes providing 48 megabits per second (Mbit/s) of neural signals.
Earlier in March, NASA’s Mars rover Curiosity arrived at a scenic rock formation nicknamed “Mont Mercou,” after a mountain in southeast France. The rover posed for a selfie in front of the Martian rock outcrop after collecting its 30th rock sample to date.
Buck Institute researchers have discovered and are developing a novel, non-invasive biomarker test that can be used to measure and track performance of senolytics: a class of drugs that selectively eliminate senescent cells. The discovery is expected to play a major role in efforts to develop treatments that would battle a myriad of chronic age-related conditions that range from arthritis to lung disease to Alzheimer’s disease and glaucoma. This biomarker is a unique signaling lipid metabolite, normally exclusively intracellular, but is released when senescent cells are forced to die. This metabolite is detectible in blood and urine, making non-invasive testing possible. With a growing list of senolytic drugs in development, detecting this metabolite via a companion test could verify performance of senolytic candidates.
“The list of age-related diseases definitively linked to cellular senescence keeps growing, as does the number of biotech companies racing to develop drugs to eliminate senescent cells,” said Buck professor Judith Campisi, Ph.D., senior scientist on the study. “While the field has never been more promising, the lack of a simple biomarker to measure and track efficacy of these treatments has been a hindrance to progress. We are excited to bring this new biomarker to the field and look forward to it being used in the clinic.”
People into aging/longevity research probably know all of what’s here already.
Aubrey de Grey has been the leading voice for antiaging, aging reversal and aging damage repair for over twenty years. He founded the SENS non-profit (Strategies for Engineered Negligible Senescence (SENS). There have been six antiaging companies that have been directly spun out of SENS is researching the hardest problems related to fixing aging damage.
Repairing damage in five of the areas of aging are now highly active areas of biotech research.
